Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.

Aberrant methylation of promoter CpG islands is known to be a major inactivation mechanism of the tumor suppressor and tumor-related genes. Some published studies suggest a relationship to exist between the methylation status of several genes and the prognosis in non-small cell lung cancer (NSCLC); hypermethylation of the specific genes may be expected to serve as a biomarker for the prognosis, after a curative resection of NSCLC. To determine the relationship between the methylation status of the tumor suppressor and the tumor-related genes, and the clinicopathologic characteristics, including the survival rate, in patients with NSCLC after a surgical resection, we studied methylation in 10 genes (DAPK, FHIT, H-cadherin, MGMT, p14, p16, RAR-beta, RASSF1A, RUNX3, and TIMP-3) in 101 NSCLC cases by methylation-specific PCR (MSP). The methylation frequencies of the 10 genes examined in NSCLC were 26% for DAPK, 34% for FHIT, 26% for H-cadherin, 14% for MGMT, 8% for p14, 27% for p16, 38% for RAR-beta, 42% for RASSF1A, 25% for RUNX3, and 12% for TIMP-3. Clinicopathologically, the patients with all stages of disease who had positive RASSF1A, RUNX3, or H-cadherin methylation status were found to have a significantly shorter duration of survival, as compared with the patients with a negative methylation status for those genes (RASSF1A:P=0.023, RUNX3:P=0.035, H-cadherin:P=0.039) in univariate analysis. Thereafter, while limiting our examination to patients with stage I disease, the patients who had a positive RASSF1A or RUNX3 methylation status were found to have a significantly shorter duration of survival, in comparison to the patients with negative methyaltion status for each of those genes (RASSF1A:P=0.022, RUNX3:P<0.01) in univariate analysis. Next, the histological differences were recognized that the patients with RUNX3 methylation had a shorter duration of survival in adenocarcinomas (ACs) (P=0.045), in contrast to those with RASSF1A methylation who had a shorter duration of survival in squamous cell carcinomas (SCCs) (P=0.021). In multivariate analysis, both positive RASSF1A methylation status, and positive RUNX3 methylation status were found to be independent prognostic factors (RASSF1A:P=0.031, RUNX3:P=0.028), as was TNM stage (P=0.004) and pleural involvement (P=0.037). In conclusion, the hypermethylation of RASSF1A or RUNX3 gene is therefore a useful biomarker to predict the prognosis in NSCLC, particularly RASSF1A due to SCCs and RUNX3 due to ACs.

[1]  Hoguen Kim,et al.  Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. , 2004, Biochemical and biophysical research communications.

[2]  J. Minna,et al.  Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. , 2001, Cancer research.

[3]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[4]  Hiroshige Nakamura,et al.  Expression of RUNX3 protein in human lung adenocarcinoma: Implications for tumor progression and prognosis , 2005, Cancer science.

[5]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[6]  T. Motoyama,et al.  Promoter hypermethylation of tumor suppressor and tumor‐related genes in non‐small cell lung cancers , 2003, Cancer science.

[7]  David A Jones,et al.  Reactivating the expression of methylation silenced genes in human cancer , 2002, Oncogene.

[8]  J. Minna,et al.  5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. , 2001, Cancer research.

[9]  D. Scherman,et al.  Antisense MBD2 gene therapy inhibits tumorigenesis , 2002, The journal of gene medicine.

[10]  J. Minna,et al.  Smoke exposure, histologic type and geography‐related differences in the methylation profiles of non‐small cell lung cancer , 2003, International journal of cancer.

[11]  Y. Shim,et al.  Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. , 2006, Cancer research.

[12]  M. Malumbres,et al.  RAS pathways to cell cycle control and cell transformation. , 1998, Frontiers in bioscience : a journal and virtual library.

[13]  Hojoong Kim,et al.  RASSF1A is not appropriate as an early detection marker or a prognostic marker for non‐small cell lung cancer , 2005, International journal of cancer.

[14]  Y. Sakao,et al.  Prognostic significance of a histologic subtype in small adenocarcinoma of the lung: the impact of nonbronchioloalveolar carcinoma components. , 2007, The Annals of thoracic surgery.

[15]  M. Takeichi.  Cadherins in cancer: implications for invasion and metastasis. , 1993, Current opinion in cell biology.

[16]  Su Jeong Song,et al.  The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC–Cdc20 complex , 2004, Nature Cell Biology.

[17]  J. Gergen,et al.  Isolation of the Drosophila segmentation gene runt and analysis of its expression during embryogenesis. , 1988, Genes & development.

[18]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Miyazono,et al.  Interaction and Functional Cooperation of PEBP2/CBF with Smads , 1999, The Journal of Biological Chemistry.

[20]  A. Marchetti,et al.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Morita,et al.  The methylation status and protein expression of CDH1, p16INK4A, and fragile histidine triad in nonsmall cell lung carcinoma , 2006 .

[22]  Y. Yatabe,et al.  RASSF1A gene inactivation in non‐small cell lung cancer and its clinical implication , 2003, International journal of cancer.

[23]  R. Tsuchiya,et al.  Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. , 2001, The Annals of thoracic surgery.

[24]  J. Minna,et al.  NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers , 2003, Oncogene.

[25]  B. Olsen,et al.  A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. , 1996, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[26]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[27]  N. Colburn,et al.  Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. , 1996, Carcinogenesis.

[28]  J. Minna,et al.  Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  Y. Shim,et al.  Aberrant methylation of H‐cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma , 2005, Cancer.

[30]  T. Motoyama,et al.  Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples , 2003, Oncogene.

[31]  A. Gazdar,et al.  Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma , 2004, Cancer.

[32]  J. Minna,et al.  Aberrant promoter methylation of multiple genes in non-small cell lung cancers. , 2001, Cancer research.

[33]  Diane D. Liu,et al.  Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[34]  T. Motoyama,et al.  Frequent Epigenetic Silencing of the p16 Gene in Non‐small Cell Lung Cancers of Tobacco Smokers , 2002, Japanese journal of cancer research : Gann.

[35]  S. Toyooka,et al.  The relationship between aberrant methylation and survival in non-small-cell lung cancers , 2004, British Journal of Cancer.

[36]  B. Simon,et al.  Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[37]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[38]  J. Behrens,et al.  Cell contacts, differentiation, and invasiveness of epithelial cells. , 1994, Invasion & metastasis.

[39]  Y. Tomizawa,et al.  Epigenetic inactivation of the RUNX3 gene in lung cancer. , 2006, Oncology reports.

[40]  S. Itohara,et al.  Causal Relationship between the Loss of RUNX3 Expression and Gastric Cancer , 2002, Cell.

[41]  Yoshiaki Ito,et al.  Cloning, mapping and expression of PEBP2αC, a third gene encoding the mammalian Runt domain , 1995 .

[42]  Hyeon Joo Lee,et al.  Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma , 2004, Laboratory Investigation.